Abstract
Seven cases of herpes simplex virus infection were treated using new antiviral agent, Ara A. For 5 patients with Kaposi varicelliform eruption, Ara A proved to be effective based on a quick recovery from high fever and skin rashes immediately after administration of the drug. However, the effect of the drug in 2 patients with genital herpes failed to be significant because of the small number of patients. Elevated complement fixation antibody titre for herpes simplex virus suggested that Ara A did not suppress the humoral immunity. No severe side effects were observed.